Perkin-Elmer Freezes Analytical LifeSciences Market With API 3000 Debut
This article was originally published in The Gray Sheet
Executive Summary
Perkin-Elmer's March debut of its API 3000 high-end liquid chromatography/mass spectrometry system preceded the firm's ability to commence shipping the product, effectively stalling sales of existing LC/MS systems in the final weeks of the firm's third fiscal quarter of 1998 (ended March 31).
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.